Navidea Biopharmaceuticals, Inc. and MacRophage Therapeutics, Inc. v. Capital Royalty Partners II, L.P., Capital Royalty Partners II - Parallel Fund "A", L.P., Parallel Investment Opportunities Partners, II, L.P., Capital Royalty Partners II (Cayman) L.P., CR Group, L.P., CRG Servicing, LLC, and Capital Royalty Partners II – Parallel Fund "B" (Cayman) L.P.

Motion Granted; Appeal Dismissed and Memorandum Opinion filed
December 28, 2023




                              In The

               Fourteenth Court of Appeals

                       NO. 14-22-00882-CV


   NAVIDEA BIOPHARMACEUTICALS, INC. AND MACROPHAGE
               THERAPEUTICS, INC., Appellants

                                V.

   CAPITAL ROYALTY PARTNERS II, L.P.; CAPITAL ROYALTY
PARTNERS II - PARALLEL FUND “A”, L.P.; PARALLEL INVESTMENT
     OPPORTUNITIES PARTNERS, II, L.P.; CAPITAL ROYALTY
 PARTNERS II (CAYMAN) L.P.; CR GROUP, L.P.; CRG SERVICING,
LLC; AND CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “B”
                   (CAYMAN) L.P., Appellees

              On Appeal from the 151st District Court
                      Harris County, Texas
                Trial Court Cause No. 2018-24442


                   MEMORANDUM OPINION
         This is an appeal from a judgment signed September 1, 2022. On December
6, 2023, appellants filed an agreed motion to dismiss the appeal. See Tex. R. App.
P. 42.1. The motion is granted. Costs are taxed against the party incurring such
costs.

         We dismiss the appeal.

                                  PER CURIAM

Panel consists of Justices Bourliot, Zimmerer and Spain.




                                         2